Merck announces recipients of €1 million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced recipients of the fifth annual Grant for Multiple Sclerosis Innovation (GMSI) during the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. This year, 77 proposals from 25 countries were submitted, representing innovative research projects taking place across the globe.
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
- Details
- Category: Novartis
Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) meeting (October 25-28, 2017 Paris, France).
BIOCAD enters the European market
- Details
- Category: Business
The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines. So far, there are seven molecules in the European portfolio of BIOCAD. These are innovative and biosimilar products, which could be used in treatment of melanoma, breast, stomach, kidney and lung cancer, rheumatoid arthritis, psoriasis and multiple sclerosis.
Roche reports strong sales growth in the first nine months of 2017
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the Group sales rose 5% to CHF 39.4 billion. Sales in the Pharmaceuticals Division increased 5% to CHF 30.6 billion. The recently launched medicines Ocrevus, Tecentriq and Alecensa contributed CHF 0.9 billion to new sales, accounting for more than half of the division's growth.
The Union for International Cancer Control and Pfizer award new round of grants totalling US$500,000 to organisations in 19 countries
- Details
- Category: Pfizer
The Union for International Cancer Control (UICC) and Pfizer Oncology have announced the names of the organisations taking part in the second phase of the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge (SPARC MBC Challenge). The 20 organisations from 19 countries that have been selected will receive grants amounting to US$500,000 in funding provided by Pfizer to
A great place to do great things: Developing game-changing technology at Abbott
- Details
- Category: Abbott
Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized Abbott on its Top Employers list, which is based on an evaluation of 23 characteristics including financial strength, easy adaptation to change, and a research-driven environment.
MSD Innovation Factory is looking for digital solutions for anaesthesiologists
- Details
- Category: Business
MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation room) or their team building with surgeons. As a leading pharmaceutical company, MSD is aware of the need to incorporate innovation to deliver the best possible value to healthcare professionals, patients and customers.
More Pharma News ...
- Merck brings customers closer to gene therapy product commercialization
- FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
- FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review
- AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology
- Pfizer reviewing strategic alternatives for Consumer Healthcare business
- Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
- Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams